Ganzinger U, Schatz F, Haberl H, Haslberger A, Schiel H, Hitzenberger G
Int J Clin Pharmacol Ther Toxicol. 1987 Mar;25(3):152-6.
The pharmacokinetics of latamoxef and CPW 86-363, a novel carboxy-pyrazol-cephalosporin, were evaluated in healthy volunteers after intravenous bolus injection of 1 g. Based on concentration-time courses in serum both cephalosporins showed similar distribution properties, although CPW 86-363 was eliminated significantly faster. The route of elimination of latamoxef was mainly via the urine, whereas CPW 86-363 was also excreted into the bile. N-methylthiotetrazole, which is the common side chain in position 3 of both cephalosporins, was found in the serum as well as in the urine. Its rate and extent of formation was higher for latamoxef than for CPW 86-363 and depends rather on the instability of the parent compound than on metabolic transformation. This is supported by studies on the in vitro degradation of both derivatives. The relevance of these findings are discussed in view of secondary coagulopathies, which are associated with cephalosporins having a N-methylthiotetrazole side chain.
在健康志愿者静脉推注1g新型羧基吡唑头孢菌素拉氧头孢和CPW 86 - 363后,对其药代动力学进行了评估。根据血清中的浓度 - 时间过程,两种头孢菌素显示出相似的分布特性,尽管CPW 86 - 363的消除明显更快。拉氧头孢的消除途径主要是通过尿液,而CPW 86 - 363也排泄到胆汁中。在血清和尿液中都发现了N - 甲基硫代四唑,它是两种头孢菌素3位的常见侧链。拉氧头孢中其形成的速率和程度高于CPW 86 - 363,并且更多地取决于母体化合物的不稳定性而非代谢转化。这得到了两种衍生物体外降解研究的支持。鉴于与具有N - 甲基硫代四唑侧链的头孢菌素相关的继发性凝血病,对这些发现的相关性进行了讨论。